Asensus initiates Senhance program in Germany

Asensus Surgical (NYSE:ASXC) announced today that it entered into an agreement to initiate a surgical robotic […]

Asensus Surgical (NYSE:ASXC) announced today that it entered into an agreement to initiate a surgical robotic program in Germany.

Klinikum Idar-Oberstein Hospital entered into a lease agreement to use a Senhance surgical system. Senhance, Asensus’ flagship offering for its Performance-Guided Surgery, is a first-of-its-kind digital laparoscopic surgical robot. It uses augmented intelligence to perform procedures through machine learning.

Senhance users span the globe, with Mayo Clinic recently taking up a pediatric program in the U.S. and several programs ongoing in Japan.

This announcement marks another step forward in Germany, where Asensus began a Senhance program last year. The company installed a Senhance surgical system at University Hospital Tübingen in Germany in July 2022. The Department of Gynecology at the University Hospital Tübingen previously initiated its Senhance Surgical program in December of 2021.

Dr. Christos Zigouris said in a news release that adding Senhance at Idar-Oberstein raises the bar for patient care. Zigouris, chief physician clinic for general, visceral, and minimally invasive surgery, said it marks a “significant leap forward” for the hospital.

“We are pleased to collaborate with Klinikum Idar-Oberstein Hospital as they aim to enhance patient outcomes through advanced minimally invasive surgery. The innovative features of the Senhance System, combined with the established laparoscopic approach, will bring valuable enhancements to the Idar-Oberstein Hospital,” said Anthony Fernando, president and CEO of Asensus Surgical. “We look forward to working with Dr. Christos Zigouris and team to ensure the success of their team’s Senhance program.”

Original Article: (https://www.massdevice.com/asensus-initiates-senhance-program-in-germany/)